Cure8 research brief
This study provides real-world data suggesting the oral α4-integrin antagonist carotegrast methyl can improve patient-reported stool frequency and rectal bleeding in many people with ulcerative colitis who did not respond adequately to 5‑ASA.
It also reports a tolerability profile without serious adverse events in this cohort.
Adults with ulcerative colitis with inadequate response to 5‑ASA; gastroenterologists and IBD clinicians; researchers studying oral anti-integrin agents or real-world UC treatment outcomes.
A multicenter retrospective observational study reported real-world outcomes for carotegrast methyl, an oral α4-integrin antagonist, in patients with ulcerative colitis who had an inadequate response to 5‑ASA.
Among 180 effectiveness-evaluable patients, patient-reported symptom response at week 8 (PRO-2) was 57.8% and remission 43.3%; rates were similar or modestly higher at the end of treatment and increased through week 16. Adverse drug reactions were reported in about 16% of patients (31 of 196), with no serious events recorded in this cohort.
The study used PRO-2 (stool frequency and rectal bleeding subscores) to assess effectiveness and followed patients for up to 52 weeks (median treatment duration ~84 days).
This is a retrospective, observational series from clinical practice rather than a randomized trial; findings describe symptom changes and reported safety in this treated population but do not establish comparative efficacy.
The study is retrospective and observational (real-world practice) and uses PRO-2 as the effectiveness measure. Results describe associations in treated patients but do not come from a randomized controlled trial; generalizability beyond the studied population may be limited.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: EA Pharma Co., Ltd; Kissei Pharmaceutical Co., Ltd
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...
